Grail CFO Aaron Freidin sells $3.46m in company stock

Aaron Freidin, Chief Financial Officer of GRAIL, Inc. (NASDAQ:GRAL), sold 23,619 shares of the company’s common stock on October 5, 2026. The transactions totaled approximately $3,457,585.

The shares were sold at a weighted average price of $146.39 per share. These sales represent automatic "sell-to-cover" transactions executed by a broker to cover withholding taxes upon award vesting and share delivery.

Following these transactions, Mr. Freidin directly holds 225,364 shares of GRAIL, Inc. common stock.The sale comes as GRAIL’s stock has experienced significant volatility, with shares currently trading at $132.90, down from the $146.39 sale price. Despite the recent pullback, the stock has delivered a remarkable 170% return over the past six months and 112% over the past year, according to InvestingPro data. The company’s beta of 2.84 indicates substantially higher volatility than the broader market.InvestingPro analysis suggests GRAIL is currently overvalued relative to its Fair Value, placing it among stocks on the most overvalued list. Investors seeking deeper insights can access GRAIL’s comprehensive Pro Research Report, one of 1,400+ available reports that transform complex data into actionable intelligence.

In other recent news, Grail Inc. has seen several developments surrounding its Galleri multi-cancer early detection test. The FDA advisory committee recently voted in favor of the test’s safety with a 10-0 vote and its effectiveness with a 6-4 vote, while also determining that the benefits outweigh the risks. Following this, Canaccord Genuity raised its price target for Grail shares to $150, maintaining a Buy rating, and Mizuho increased its target to $100, maintaining a Neutral rating. Additionally, FDA staff reviewers did not find major concerns with the test, which is designed to detect over 50 types of cancer, according to briefing documents released before an advisory committee meeting.

RBC Capital initiated coverage on Grail with a Sector Perform rating and a price target of $84, highlighting concerns about reimbursement and adoption despite the significant market opportunity. Canaccord Genuity reiterated a Buy rating and an $80 price target after the favorable FDA panel vote. The developments around Grail’s Galleri test continue to draw attention from analysts and investors, particularly as the company progresses towards potential FDA approval.